

Meeting of the Board of the Western Sydney Local Health District

No. 2017/73
Date: Tuesday, 12 September 2017
Venue: Seminar Room 6102
Charles Perkins Centre University of Sydney

Minutes

Present: Richard Alcock (Chair), Kathy Baker, Narelle Bell, Andrew Bernard, Elizabeth Crouch, Di O'Halloran, Chris Liddle, Don Nutbeam, Jane Spring and Bruce Turner

Ex officio: Joanne Edwards, Andrew Newton, Danny O'Connor, Leena Singh.

Secretariat: Doug Catchpole
Ngoc Tran (Executive Support)

Hosts: Belinda Hutchinson, Chancellor, University of Sydney
Michael Spence, Vice Chancellor, University of Sydney

Invited: Tony Barry, Biomedical Engineer WSLHD
Karen Borg, Chief Executive Officer, Jobs for NSW
Tim Fountaine, Partner, McKinsey
Daniel Kenny, CEO and Director, OncoSil Medical
Simon Kennedy, Partner, McKinsey
Stephen Leeder, Emeritus Professor of Public Health and Community Medicine
David Markwell, Manager, Intellectual Property and Commercialism WSLHD
Rebecca Murray, Vice Principal for Strategy, University of Sydney
Tony Stephens, Strategy and Innovation Executive, Jobs for NSW

Meeting commenced: 4.30pm

Quorum: A quorum was met.

Item 1 Welcome and Leave of Absence

The Chair acknowledged the occasion, recognising the significance of the 42 year partnership with University of Sydney.

The meeting was opened and members welcomed to the seventh board meeting of 2017.

The Chair welcomed the invited speakers, Stephen Leeder, David Markwell, Karen Borg and Daniel Kenny.

The Chair welcomed observers Tony Barry, Tim Fountaine, Simon Kennedy, Rebecca Murray and Tony Stephens.

Leave of Absence: Jeremy Chapman, Michael Edye, Andrew Pesce.

Acknowledgement of Country

WSLHD Board and guests acknowledged the traditional custodians of the lands, of elders past and present, on which the meeting had taken place.

The Board reflected on the Premier and State priorities aimed at closing the gap for the Indigenous population in areas of life expectancy, health, education and employment. Western Sydney has the largest urban Indigenous population in Australia with the opportunity for members of the Board, to show leadership and commitment towards developing and implementing a Reconciliation Action Plan (RAP) to bridge the gap.

Item 2 Declarations of Changes in Material Circumstances

No formal declarations received.

Item 3 Strategy (Invited speakers)

Item 3.1 IP & Commercialisation case Study: The Mu Catheter Stephen Leeder, Emeritus Professor, Public Health and Community Medicine David Markwell, Manager, Intellectual Property and Commercialism Tony Barry, Biomedical Engineer, Inventor (Q&A)

WSLHD supports commercialisation of intellectual property to potential companies. Members were referred to the presentation and accompanying documents on an Intellectual Property (IP) case study.

The IP case study is on a device designed for the treatment of patients with hypertension. Unlike the current treatments available, the device is able to ablate more renal nerves, whilst sparing the artery. The technology was co-invented by a biomedical engineer and cardiologist. The intellectual property is jointly owned with University of Sydney. The project has been awarded funding by the NSW Medical Device Fund to complete preclinical development.

Members discussed the potential of investment in Research and Development (R&D). Product investment may provide modest financial return, however it is recognised that there is an opportunity to bring innovation to a wider audience with focus on research dissemination and partnership potential. Members agreed the focus is leading innovation to improve patient care.

The success of the case study was commended and Members were asked what WSLHD could do to create future success stories. Members identified improved access to clinicians, facilities, IP education and hypothesis of success/failure of product early on as areas to improve R&D at WSLHD.

As part of the Westmead redevelopment, there will be an Innovation Centre on the Westmead precinct to be built to include a concierge facility to provide an IP connecting point for inventors.

Action and decision: Presentation NOTED.

Item 3.2 **Work to date to attract new work to the western Sydney precinct**
Karen Borg, Chief Executive Officer, Jobs for NSW
Daniel Kenny, Chief Executive Officer and Managing Director, OncoSil Medical

Members were referred to the presentation previously presented at an Industry dinner with a summary provided to the Board.

Jobs for NSW is a concierge to the NSW Government to create jobs and support clients as they grow. One of the Jobs for NSW strategy is to provide start up opportunities with the Pilot Cluster Program. Western Sydney is a part of the Westmead Health and Education Cluster consisting of Westmead Hospital, The Children's Hospital at Westmead, Cumberland Hospital, Westmead Private Hospital, Westmead Institute for Medical Research, Children's Medical Research Institute, The University of Sydney, Western Sydney University and Parramatta North Urban Transformation project. The cluster aims to share talent, establish a strong identity, improve connection and exchange of ideas and promote economic diversity.

It was noted successful clusters leverage existing sources of competitive advantage such as existing infrastructure and complementary services and existing human capital.

The current observation is that there is an opportunity for alignment between government, industry and academia to create a globally significant health and education precinct. Data is the crucial asset to keep a competitive advantage.

WSLHD aims to be outwardly focused to benefit the consumer. WSLHD and University of Sydney support the presentation and comments provided and recognise the opportunity to make the right decisions for Western Sydney.

WSLHD welcomes the collaboration with University of Sydney with a lot of detailed work happening for the next stage.

Action and decision: Presentation NOTED.

Item 3.3 **Westmead Precinct vision**
Leena Singh, Acting Chief Finance Officer,
Director of Strategic Business Development & Commercial Services

A presentation was provided on the Westmead precinct vision incorporating the investments from the University, government and the private sector.

Action and decision: Presentation NOTED.

Item 4 **Standing reports**

Members agreed that matters arising from standing reports could be raised out of session.

Action and decision: Board Members to raise any matters to the Board Secretariat and / or Board Chair out of session.

Next Meeting



The next meeting of the 2017 WSLHD Board is scheduled Tuesday, 10 October 2017, 4.30pm-7.30pm at the O3Hub, Level 3 Oral Health Building, Westmead Hospital.

Close

The meeting closed at 6.15pm.